Back to Headlines
Environment
Apr 09, 2026

Self‑Inflicted Snakebites Drive Near‑Universal Antivenom as Climate Change Heightens Global Risk

AI Summary
Window‑cleaner Tim Friede endured more than 200 deliberate snakebites over two decades to develop antibodies that could underpin a broad‑spectrum antivenom, a breakthrough that may curb the estimated 138,000 annual snakebite deaths as climate change forces more human‑snake encounters.

As rising temperatures push snakes and humans into closer contact, the world faces an estimated 5.5 million snakebites each year, resulting in 138,000 deaths and 400,000 lasting disabilities. In response, a Wisconsin‑based amateur scientist has taken an extreme route to help solve the crisis.

For almost 20 years, Tim Friede, a former window cleaner, allowed some of the planet’s most lethal snakes to bite him, accumulating over 200 intentional bites. His goal: to provoke his own immune system into producing antibodies that could be harvested for a near‑universal antivenom.

The endeavor has been perilous. Friede survived a coma after being bitten by two cobras within an hour, endured anaphylactic shocks, lost tissue in a finger, and even had to cut necrotic muscle from his leg. Yet he persisted, eventually becoming immune to the inland taipan—the world’s most venomous snake, whose single bite can kill more than 100 people.

In 2019, California biotech firm Centivax hired Friede to extract his antibodies. Early laboratory work showed that his serum can neutralise toxins from 19 elapid species, including cobras, mambas, taipans, coral snakes and kraits—roughly half of all venomous snakes worldwide.

The next step is a veterinary trial in Australia, slated for later this year, before any human application. If successful, the antivenom could dramatically reduce the burden of snakebite in low‑income regions across Asia and Africa, where most victims live.

Climate scientists warn that warming climates will expand snake habitats and increase human exposure, as illustrated by the recent surge of rattlesnake bites in California’s Ventura County. This amplifies the urgency for scalable, affordable antivenoms, especially as international aid budgets face cuts and manufacturing capacity remains insufficient.

Friede’s unconventional path underscores a broader lesson: confronting emerging health threats may require bold, unconventional science, but the potential payoff—a life‑saving treatment for millions—could be transformative.